Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 24, 2008. The document serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMR), specifically detailing share-based awards granted on July 23, 2008.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation structures and specific award details rather than consolidated financial performance.
Material Changes and Award Details
On July 23, 2008, GSK granted awards under two specific plans to Executive Directors and PDMRs. The material details of these grants are as follows:
- Performance Share Plan:
- Measurement Period: January 1, 2008, to December 31, 2010.
- Condition: Vesting is based on Total Shareholder Return (TSR) relative to a comparator group of 14 pharmaceutical companies.
- Vesting Scale: No vesting below median; 35% at median; 100% if ranked 1st or 2nd.
- Recipients: Mr. A P Witty (Executive Director) and Mr. S A Hussain (PDMR).
- Share Option Plan:
- Measurement Period: January 1, 2008, to December 31, 2010.
- Condition: Vesting is based on Earnings Per Share (EPS) growth exceeding the Retail Price Index (RPI) by 3% per annum.
- Vesting Scale: 50% vesting at RPI + 3%; 100% vesting at RPI + 6% or more.
- Exercise Price: £12.205 per Ordinary share.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, or general management commentary regarding business operations. The primary risk disclosed relates to the performance conditions of the awards: if GSK fails to meet the specified TSR or EPS growth targets relative to the comparator group or RPI, the awards will lapse entirely or partially.
Important Facts for Investors to Verify
- Confirm the specific TSR ranking of GSK against the 14 comparator companies (Abbott, AstraZeneca, Amgen, etc.) to assess potential vesting of the Performance Share Plan.
- Verify GSK's compound annual EPS growth rate relative to the RPI to determine the vesting percentage of the Share Option Plan.
- Note that the awards are contingent on the Remuneration Committee's determination that performance conditions are satisfied.
- Recognize that this filing is a regulatory disclosure of executive compensation and does not reflect the company's overall financial health or operational results for the period.